{"entity":{"id":"nct07128199","kind":"trial","name":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","aka":["REZILIENT4"],"tldr":"A phase 3 trial testing Zipalertinib in non-small-cell lung cancer, active and no longer recruiting.","summary":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumour Resection is a phase 3 interventional study registered as NCT07128199, led by Taiho Oncology, and active but no longer recruiting on the registry. Official title: A Randomised, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumour Resection (REZILIENT4). Planned enrolment is 360 participants (estimated). The study started in 2025-12-22 and primary completion is expected in 2029-10-01. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07128199","url":"https://clinicaltrials.gov/study/NCT07128199"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc","resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zipalertinib"],"companies":["taiho-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07128199","phase":"3","setting":"A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)","sponsor":"Taiho Oncology","participation":[{"nct":"NCT07128199","source":"https://clinicaltrials.gov/study/NCT07128199","fetchedAt":"2026-10-07T16:55:27.525Z","studySha256":"287f57f5af81129fcffd6cc1cb076bd4078c9c1550d2040cf658321de62ae4ac","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-26","leadSponsor":"Taiho Oncology, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":360,"enrolmentType":"ESTIMATED","siteCount":252,"recruitingSiteCount":0,"countries":["Argentina","Australia","Belgium","Brazil","Canada","France","Germany","Greece","Hong Kong","Italy","Japan","Malaysia","Mexico","Netherlands","Peru","Poland","Romania","Singapore","South Korea","Spain","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-12-22","startedType":"actual","enrolled":360,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07128199/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"drug":[{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/"}],"company":[{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/"}]}}